Immunovaccine to Hold Webcast and Conference Call to Discuss Clinical Data From Its Collaborative Combination Immunotherapy Trial in Advanced Ovarian Cancer

HALIFAX, Nova Scotia, Dec. 04, 2017 -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that it will hold a webcast and conference call tomorrow (Tuesday, December 5, 2017) at 8:00 a.m. ET.

The purpose of this conference call is to share top-line clinical data from its ongoing Phase 1b trial evaluating the safety and efficacy of Immunovaccine’s lead immuno-oncology candidate, DPX-Survivac, in combination with Incyte’s IDO1 enzyme inhibitor epacadostat, and low-dose cyclophosphamide in patients with advanced ovarian cancer. Immunovaccine is conducting the trial in collaboration with Incyte Corporation.

The webcast will be preceded by a press release announcing the findings from the trial thus far.

Conference Call and Webcast Information
The call can be accessed by dialing (844) 461-9932 (U.S. and Canada) or (636) 812-6632 (International) with the conference ID# 3558749. You can access the live audio webcast and presentation via this link, or by pasting this URL in your browser: https://edge.media-server.com/m6/p/9u4kwnce.

About Immunovaccine
Immunovaccine Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. Immunovaccine develops T cell-activating cancer immunotherapies and other vaccine candidates based on DepoVax™, the Company’s patented platform that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell-activating therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1b study with Incyte Corporation assessing lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer as well as two Phase 2 trials with Merck in ovarian cancer and DLBCL. The Company is also exploring additional applications of DepoVax, including DPX-RSV, an innovative vaccine candidate for respiratory syncytial virus (RSV), which has recently completed a Phase 1 clinical trial. Immunovaccine also has ongoing clinical projects to assess the potential of DepoVax to address malaria and the Zika virus. Connect at www.imvaccine.com.

Immunovaccine Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

Contacts for Immunovaccine:

MEDIA 
Mike Beyer, Sam Brown Inc.
T: (312) 961-2502 E: [email protected]

INVESTOR RELATIONS
Pierre Labbé, Chief Financial Officer
T: (902) 492-1819 E: [email protected]

Patti Bank, Managing Director, Westwicke Partners
O: (415) 513-1284
T: (415) 515-4572 E: [email protected]